RxDoctor Payments Data

Odise Cenaj, MD

Anatomic Pathology & Clinical Pathology · Boston, MANPI 1063845550

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $442 of the $532 with a category attached, or 83.1%. It is spread thinly across 10 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $181 and has fallen 86.8% since, to $24 in 2025.

$532in general payments, 2019–2025

Across 23 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$119
  • Amgen$104
  • Redhill Biopharma Inc.$80
  • Phathom Pharmaceuticals, Inc.$67
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$52
  • AbbVie$28
  • plus $83 from 4 others

What the payments were for

  • Food & beverage$44283%
  • Education$9017%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$532 in reported general payments places this provider in the 70th percentile of 196 anatomic pathology & clinical pathology providers in Massachusetts.

See all anatomic pathology & clinical pathology providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$226,882
Medicare patients
1,132
Services billed
6,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology & clinical pathology in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →